World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Imbed Biosciences Announces CMS Assignment of HCPCS Code A2040 for Microlyte® PainGuard™

Cision PR Newswire by Cision PR Newswire
April 1, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Code assignment supports billing clarity and claims reporting for Imbed’s synthetic antimicrobial wound matrix with localized, non-opioid pain management

MIDDLETON, Wis., April 1, 2026 /PRNewswire/ — Imbed Biosciences today announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a Healthcare Common Procedure Coding System (HCPCS) Level II code, A2040 , to Microlyte® PainGuard™ , the company’s synthetic wound matrix incorporating silver for antimicrobial activity and lidocaine HCl for localized pain management.


Imbed Biosciences logo (PRNewsfoto/Imbed Biosciences)

The new code is effective April 1, 2026 and enables healthcare providers to report Microlyte® PainGuard™ on claims submitted to payers that recognize HCPCS Level II codes. Code assignment represents an important step in establishing billing clarity, supporting claims visibility, and facilitating payer engagement as providers evaluate appropriate use across clinical settings.

“Assignment of an HCPCS A‑code is an important step in supporting appropriate billing for Microlyte® PainGuard™,” said Terry Bromley, CEO of Imbed Biosciences. “This designation helps provide clarity for providers as they incorporate the product into their clinical workflows.”

Microlyte® PainGuard™— Imbed’s recently introduced product —is designed to provide a fully synthetic, antimicrobial, moist wound‑healing environment while incorporating non‑opioid, localized pain management functionality . The product builds on Imbed’s Synthetic Antimicrobial Matrix (SAM) Technology platform and is intended to support wound care across a range of acute and chronic indications.

HCPCS Level II codes are used to identify products, supplies, and services not described by CPT® codes and are maintained by CMS through its national HCPCS coding process. Assignment of a Level II code allows for standardized product identification on healthcare claims and may support administrative efficiency for providers and payers.

Important Reimbursement Notice:
 HCPCS code assignment does not imply coverage, payment, or a specific reimbursement level. Coverage and payment decisions are made by individual payers and are subject to their respective policies, provider contracts, and patient‑specific circumstances.

CPT® is a registered trademark of the American Medical Association.

Media Contact:
Hillary Rush, Vice President, Marketing, Imbed Biosciences
Email: hrush@imbedbio.com

About Imbed Biosciences Imbed Biosciences is a privately held medical device company advancing the next generation of wound care through its Synthetic Antimicrobial Matrix Technology. The company’s platform incorporates multiple therapeutic agents into an ultra thin, biocompatible matrix that helps support skin regeneration in both chronic and acute wounds. Imbed’s expanding product portfolio is engineered to reduce infection risk, alleviate pain, and promote healing across the entire wound care continuum.

For more information, visit www.imbedbio.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/imbed-biosciences-announces-cms-assignment-of-hcpcs-code-a2040-for-microlyte-painguard-302732037.html

SOURCE Imbed Biosciences

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

    0 shares
    Share 0 Tweet 0
  • Mendez & Sanchez Finds Three Counties Accounted for Nearly Two-Thirds of California Rideshare Trips

    0 shares
    Share 0 Tweet 0
  • Highmark Health Reports Revenue of $26.5 billion, $741 million in Operating Income, for Nine Months ended Sept. 30, 2026

    0 shares
    Share 0 Tweet 0
  • AZ Blue Health Choice Expands Access to Resources for Page Families

    0 shares
    Share 0 Tweet 0
  • Payoneer Receives OCC Conditional Approval to Form Stablecoin National Trust Bank

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler